ArticleInvestigative ophthalmology & visual science2025
Therapeutic Potential of Graphene Quantum Dots on Pterygium Cells.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the therapeutic potential of graphene quantum dots (GQDs) in modulating key pathological processes in pterygium, including abnormal cell proliferation, migration, and extracellular matrix remodeling. Methods: Primary fibroblast cells from human pterygium and conjunctival tissues were cultured and treated with GQDs (6.25-100 µg/mL). Cell cytotoxicity and viability were assessed using live/dead and CCK-8 assays. Cell migration was evaluated via scratch wound-healing assays. Microtubule integrity was analyzed using α-tubulin immunocytochemistry and super-resolution stochastic optical reconstruction microscopy imaging. Expression of pathological proteins (cyclin D1, CDK2, periostin, matrix metalloproteinase [MMP]-3, and MMP-9) was quantified by Western blotting. Results: GQDs selectively impaired pathological behaviors in pterygium fibroblasts, reducing viability and migration in a dose-dependent manner, with minimal effects on conjunctival fibroblasts. Stochastic optical reconstruction microscopy imaging revealed GQD-induced microtubule fragmentation in pterygium fibroblasts. GQDs also significantly downregulated cyclin D1, CDK2, periostin, MMP-3, and MMP-9. Conclusions: GQDs suppress multiple pathologic features of pterygium, including selective cytotoxicity, downregulation of key molecular mediators (cyclin D1, periostin, MMP-3, and MMP-9), and a novel mechanism involving microtubule fragmentation. These findings support the potential of GQDs as a noninvasive therapeutic strategy to suppress pterygium progression and decrease postoperative recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.